- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 118525-40-9] Icaritin
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-N0678 |
| Brand: | MCE |
| CAS: | 118525-40-9 |
Overview
| MDL | MFCD22422519 |
|---|---|
| Molecular Weight | 368.38 |
| Molecular Formula | C21H20O6 |
| SMILES | O=C1C(O)=C(C2=CC=C(OC)C=C2)OC3=C(C/C=C(C)\C)C(O)=CC(O)=C13 |
Summary
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornu Maxim. and potently inhibits proliferation of K562 cells ( IC 50 of 8 µM) and primary CML cells ( IC 50 of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis [1] [2] [3 .
In Vitro
Icaritin (4-64 µM; 48 hours; K562, imatinib-resistant cells and primary CML cells) treatment inhibits proliferation of K562, imatinib-resistant cells and primary CML cells
[1]
.
Icaritin (0-64 µM; 48 hours; K562 and primary cells) treatment induces K562 or primary cells apoptosis in an concentration dependent manner
[1]
.
Icaritin (32 µM; K562 cells) treatment increases cell population in the sub-G1 phase in K562 cells
[1]
.
Icaritin (0-64 µM; 48 hours; K562 cells) treatment inhibits MAPK/ERK/JNK downstream signaling and diminishes Jak2/Stat3/Akt expression. Icaritin treatment also significantly inhibits Bcl-2 protein expression and up-regulated Bax protein expression in K562 with a dose-dependent manner accompanied by the cleavage activation of caspase-3 or caspase-9, and a down-regulated expression of Apaf-1
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [1]
| Cell Line: | K562, imatinib-resistant cells and primary CML cells |
| Concentration: | 4 µM, 8 µM, 16 µM, 32 µM and 64 µM |
| Incubation Time: | 48 hours |
| Result: | Inhibited cell proliferation. |
Apoptosis Analysis [1]
| Cell Line: | K562 or primary cells |
| Concentration: | 0 µM, 4 µM, 8 µM, 16 µM, 32 µM and 64 µM |
| Incubation Time: | 48 hours |
| Result: | Induced K562 or primary cells apoptosis. |
Cell Cycle Analysis [1]
| Cell Line: | K562 cells |
| Concentration: | 32 µM |
| Incubation Time: | |
| Result: | Cell population in the sub-G1 phase was increased. |
Western Blot Analysis [1]
| Cell Line: | K562 cells |
| Concentration: | 0 µM, 4 µM, 8 µM, 16 µM, 32 µM and 64 µM |
| Incubation Time: | 48 hours |
| Result: | Inhibited MAPK/ERK/JNK downstream signaling and diminishes Jak2/Stat3/Akt expression. |
In Vivo
Icaritin (4-8 mg/kg; intraperitoneal injection; daily; for 10 weeks; female NOD-SCID nude mice) treatment could prolong lifespan of NOD-SCID nude mice inoculated with K562 cells without suppression of bone marrow in mouse leukemia model [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female NOD-SCID nude mice (6-8 weeks old) with K562 cells [1] |
| Dosage: | 4 mg/kg and 8 mg/kg |
| Administration: | Intraperitoneal injection; daily; for 10 weeks |
| Result: | Could prolong lifespan of NOD-SCID nude mice inoculated with K562 cells without suppression of bone marrow. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02496949 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Shenogen Biomedical Co., Ltd |
Solid Tumors
|
November 2011 | Phase 1 |
| NCT03236649 | Beijing Shenogen Biomedical Co., Ltd|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Eastern Theater General Hospital,QinHuai District Medical Area|Peking University Cancer Hospital & Institute|Chinese PLA General Hospital|Beijing Hospital|General Hospital of Chinese Armed Police Forces|Guang´anmen Hospital of China Academy of Chinese Medical Sciences|Jinan Central Hospital|Linyi Cancer Hospital|The First Affiliated Hospital of Anhui Medical University|Anhui Provincial Hospital|The First Affiliated Hospital with Nanjing Medical University|The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China|Nanfang Hospital of Southern Medical University|First People´s Hospital of Foshan|Affiliated Cancer Hospital & Institute of Guangzhou Medical University|Tianjin Medical University Cancer Institute and Hospital|The Fourth Hospital of Hebei Medical University|Hunan Cancer Hospital|The First Hospital of Jilin University|307 Hospital of PLA|Fudan University|Henan Cancer Hospital|Jilin Provincial Tumor Hospital|First Affiliated Hospital of Harbin Medical University|First Affiliated Hospital Bengbu Medical College|The First Affiliated Hospital of Soochow University|Tongji Hospital|Beijing YouAn Hospital |
Hepatocellular Carcinoma (HCC)
|
September 20, 2017 | Phase 3 |
| NCT01278810 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Shenogen Biomedical Co., Ltd |
Metastatic Breast Cancer
|
November 2010 | Phase 1 |
| NCT03236636 | Beijing Shenogen Biomedical Co., Ltd|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|NanJing PLA 81 Hospital|Peking University Cancer Hospital & Institute|Beijing Hospital|Guang´anmen Hospital of China Academy of Chinese Medical Sciences|Jinan Central Hospital|Linyi Tumour Hospital|The First Affiliated Hospital of Anhui Medical University|Anhui Provincial Hospital|The First Affiliated Hospital with Nanjing Medical University|The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China|Nanfang Hospital of Southern Medical University|First People´s Hospital of Foshan|Affiliated Cancer Hospital & Institute of Guangzhou Medical University|Hebei Medical University Fourth Hospital|The First Hospital of Jilin University|Haikou People´s Hospital|Fudan University|West China Hospital|Chongqing Traditional Chinese Medicine Hospital|Chifeng Municipal Hospital|The Affiliated Hospital of Hangzhou Normal University|The First Affiliated Hospital of Zhengzhou University|Guilin Medical University, China|The Third Xiangya Hospital of Central South University|Yunnan Provincial Hospital of Traditional Chinese Medicine|The Sixth People´s Hospital of Shenyang |
Advanced HBV-Related Hepatocellular Carcinoma (HCC)
|
September 8, 2017 | Phase 3 |
| NCT01972672 | Beijing Shenogen Biomedical Co., Ltd|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|NanJing PLA 81 Hospital|307 Hospital of PLA|Qingdao University |
Hepatocellular Carcinoma (HCC)
|
October 2013 | Phase 2 |
| NCT05594927 | Beijing Shenogen Biomedical Co., Ltd |
Hepatocellular Carcinoma
|
October 31, 2022 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 15.62 mg/mL ( 42.40 mM ; Need ultrasonic)
H 2 O : 1.2 mg/mL ( 3.26 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7146 mL | 13.5729 mL | 27.1459 mL |
| 5 mM | 0.5429 mL | 2.7146 mL | 5.4292 mL |
| 10 mM | 0.2715 mL | 1.3573 mL | 2.7146 mL |
-
1.
-
2.
Add each solvent one by one: 50% PEG300 >> 50% saline
Solubility: 1.51 mg/mL (4.10 mM); Suspended solution; Need ultrasonic
References
- [1] Zhu Jf, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720.
- [2] Yao D, et al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264.
- [3] Guo Y, et al. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011 May 11;658(2-3):114-22.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.